Latest News & Features
Biotechnology
The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals. 18 January 2024
Biotechnology
Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal. 18 January 2024
Americas
Biotech company submitted a petition challenging an ‘incorrect’ ruling by the Court of Appeals for the Federal Circuit | Earlier decision invalidated several of Vanda’s patents in its sleep drug dispute against a pair of big pharma firms. 16 January 2024
Big Pharma
US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval. 16 January 2024
Big Pharma
Case concerns a supplementary protection certificate granted to Gilead by Finland’s Patent Office for a HIV drug |CJEU judges contradict AG opinion on whether a Finnish regime is at odds with an EU directive. 11 January 2024
Biotechnology
SCOTUS ignored Fed Circ cases and so-called Wands factors in reaching enablement decision | Pivotal question left unanswered | New guidance ‘provides clarity’ and reinforces status quo on enablement decisions. 11 January 2024
Generics
Judge says Bayer racked up high costs ‘in pursuit of vague point of principle’ | Teva and others wanted presentation slides as part of patent invalidity suit. 9 January 2024
Big Pharma
Generics companies have often inveighed against the “arbitrary and capricious” rule | Judicial immunity granted to Vidal’s decisions at odds with Congress and SCOTUS precedent, say generics and big tech. 9 January 2024
Big Pharma
Dispute hinges on clauses set out in decade-old settlement and licensing agreement | Federal Circuit unpersuaded by arguments suggesting that a federal court erred in denying a preliminary injunction. 4 January 2024
Americas
California-based drugmaker lost Hatch-Waxman Act case after judge ruled it had failed to show patent infringement | Corcept CEO ‘confident’ decision will be reversed on appeal. 4 January 2024